Determining whether an individual has abnormal levels of Aβ and/or tau, and thereby establishing a probable etiology for cognitive decline and later impairment, can now reliably be achieved using fluid and imaging biomarkers1,2. This evidence concerns the gene MAPT and Mental deterioration.